Figure S8 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer | Synapse
September 16, 2025
Figure S8 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Puntos clave
The treatment strategy shows improved outcomes in pancreatic cancer models with MTAP deletion and KRAS mutations.
Utilizing the combination of PRMT5 inhibitors and KRAS inhibitors demonstrates a significant effect on cell viability.
GSEA analysis reveals changes in cell signaling pathways when treated with PRMT5 inhibitors and KRAS inhibitors.
These findings may enhance therapeutic approaches for difficult-to-treat pancreatic cancer cases.
Resumen
Figure S8 shows GSEA of PRMT5i- and G12Di-treated cells.
Preguntar a la IA
Me gusta
Guardar
Compartir
Preguntar a la IA
Me gusta
Guardar
Compartir
Cite This Study
Drizyte‐Miller et al. (Mon,) studied this question.